17659-49-3
17659-49-3
Chemical Structure
Racanisodamine
- CAS No.: 17659-49-3
- Formula:C17H23NO4
- Molecular Weight:305.37
IUPAC Name: 6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate
InChIKey: WTQYWNWRJNXDEG-UHFFFAOYSA-N
SMILES: O=C(OC1CC(N2C)CC(O)C2C1)C(CO)C3=CC=CC=C3
Biological Activity: Racanisodamine is an orally active, non-selective Muscarinic Acetylcholine Receptor (mAChR) antagonist. Racanisodamine is a racemate of Anisodamine, and the two share similar pharmacological effects. Racanisodamine is an active ingredient of eye drops for myopia control. Racanisodamine can be used in research on myopia and late dumping syndrome[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Racanisodamine | 98.75% | Racanisodamine is an orally active, non-selective Muscarinic Acetylcholine Receptor (mAChR) antagonist. Racanisodamine is a racemate of Anisodamine, and the two share similar pharmacological effects. Racanisodamine is an active ingredient of eye drops for myopia control. Racanisodamine can be used in research on myopia and late dumping syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Racanisodamine (Standard) | ≥98% | Racanisodamine Standard is the analytical standard of Racanisodamine (HY-N2064). This product is intended for research and analytical applications. Racanisodamine is an orally active, non-selective Muscarinic Acetylcholine Receptor (mAChR) antagonist. Racanisodamine is a racemate of Anisodamine, and the two share similar pharmacological effects. Racanisodamine is an active ingredient of eye drops for myopia control. Racanisodamine can be used in research on myopia and late dumping syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chen Z, et al. Effects of 0.05% racanisodamine on pupil size and accommodation. Optometry and vision science : official publication of the American Academy of Optometry. 2010 Dec;87(12):966-70. [Content Brief]
- [2]. Chen G, et al. Use of Racanisodamine for Treating Delayed Late Dumping Syndrome. Dig Dis Sci. 2026 Oct;71(10):4539-4541. [Content Brief]
